AMR Action Fund is a public-private partnership dedicated to investing in the development of new antimicrobial therapeutics. It targets biotech companies creating treatments for life-threatening antimicrobial-resistant infections, aiming to launch 2 to 4 novel antibiotics by 2030. The fund also advocates for policy solutions to sustain innovation in antimicrobial drug development.
Recent Transactions involving AMR Action Fund
| Deal | Target | Platform | Buyer | Industry |
|---|---|---|---|---|
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing |
Adaptive Phage Therapeutics |
BiomX |
Cystic Fibrosis FoundationAMR Action FundOrbiMedDeerfield Management CompanyNantahala Capital |
Biotechnology |
The Lower and Middle Market M&A Platform
See how PrivSource can help you close more deals.
Learn more →